XOMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.44 USD | +7.39% |
|
+2.66% | +37.51% |
| May. 09 | Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M | MT |
| May. 09 | XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 8.3M | Sales 2025 * | 23.77M | Capitalization | 296M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M | Net income 2025 * | -19M | EV / Sales 2024 * | 35.7 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 12.5 x |
| P/E ratio 2024 * |
-11.1
x | P/E ratio 2025 * |
-15.6
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.55% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +7.39% | ||
| 1 week | +2.66% | ||
| Current month | +0.39% | ||
| 1 month | -1.59% | ||
| 3 months | +21.72% | ||
| 6 months | +59.00% | ||
| Current year | +37.51% |
1 week
23.69
25.74
1 month
23.6926.79
Current year
18.5727.00
1 year
13.4827.00
3 years
13.4839.02
5 years
13.4846.32
10 years
3.96119.00
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.22% | 0 M€ | -2.98% | - | |
| 0.00% | 0 M€ | +3.63% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 25.44 | +7.39% | 10,959 |
| 24-05-09 | 23.69 | -2.11% | 9,526 |
| 24-05-08 | 24.2 | -1.31% | 7,899 |
| 24-05-07 | 24.52 | -2.00% | 6,993 |
| 24-05-06 | 25.02 | +0.97% | 5,879 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-05-15
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.44
USD
Average target price
58
USD
Spread / Average Target
+127.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.51% | 296M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- XOMA Stock
